Citigroup’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2M | Hold |
25,000
| – | – | ﹤0.01% | 2664 |
|
|
2025
Q4 | $2.13M | Buy |
+25,000
| New | +$2.05M | ﹤0.01% | 2611 |
|
|
2025
Q2 | – | Sell |
-100,000
| Closed | -$7.25M | – | 5724 |
|
|
2025
Q1 | $7.25M | Buy |
100,000
+57,400
| +135% | +$4.11M | ﹤0.01% | 1608 |
|
|
2024
Q4 | $3.15M | Sell |
42,600
-79,900
| -65% | -$5.59M | ﹤0.01% | 2422 |
|
|
2024
Q3 | $8.08M | Buy |
+122,500
| New | +$8.9M | ﹤0.01% | 1465 |
|
|
2022
Q4 | – | Sell |
-150,000
| Closed | -$12.4M | – | 5821 |
|
|
2022
Q3 | $12.4M | Buy |
+150,000
| New | +$14.4M | 0.01% | 1040 |
|
|
2021
Q1 | – | Sell |
-64,700
| Closed | -$5.9M | – | 6580 |
|
|
2020
Q4 | $5.9M | Sell |
64,700
-20,300
| -24% | -$1.68M | ﹤0.01% | 1952 |
|
|
2020
Q3 | $6.78M | Sell |
85,000
-12,600
| -13% | -$983K | ﹤0.01% | 1680 |
|
|
2020
Q2 | $6.75M | Sell |
97,600
-69,500
| -42% | -$4.94M | 0.01% | 1617 |
|
|
2020
Q1 | $10.5M | Sell |
167,100
-15,900
| -9% | -$1.15M | 0.01% | 1127 |
|
|
2019
Q4 | $14.2M | Sell |
183,000
-3,900
| -2% | -$305K | 0.01% | 1196 |
|
|
2019
Q3 | $13.7M | Sell |
186,900
-3,300
| -2% | -$232K | 0.01% | 1178 |
|
|
2019
Q2 | $11.7M | Buy |
190,200
+22,500
| +13% | +$1.36M | 0.01% | 1280 |
|
|
2019
Q1 | $10.7M | Buy |
167,700
+23,100
| +16% | +$1.32M | 0.01% | 1224 |
|
|
2018
Q4 | $7.38M | Sell |
144,600
-319,800
| -69% | -$16.2M | 0.01% | 1493 |
|
|
2018
Q3 | $27M | Buy |
464,400
+411,600
| +780% | +$20.1M | 0.02% | 670 |
|
|
2018
Q2 | $2.56M | Sell |
52,800
-20,100
| -28% | -$938K | ﹤0.01% | 2466 |
|
|
2018
Q1 | $3.39M | Buy |
72,900
+31,800
| +77% | +$1.38M | ﹤0.01% | 2132 |
|
|
2017
Q4 | $1.54M | Sell |
41,100
-19,200
| -32% | -$705K | ﹤0.01% | 2913 |
|
|
2017
Q3 | $2.2M | Buy |
60,300
+11,100
| +23% | +$423K | ﹤0.01% | 2566 |
|
|
2017
Q2 | $1.94M | Buy |
49,200
+4,200
| +9% | +$153K | ﹤0.01% | 2626 |
|
|
2017
Q1 | $1.41M | Sell |
45,000
-132,300
| -75% | -$4.14M | ﹤0.01% | 2843 |
|
|
2016
Q4 | $5.54M | Buy |
177,300
+75,000
| +73% | +$2.43M | 0.01% | 1724 |
|
|
2016
Q3 | $4.11M | Sell |
102,300
-66,300
| -39% | -$2.5M | ﹤0.01% | 1838 |
|
|
2016
Q2 | $5.61M | Buy |
168,600
+112,500
| +201% | +$3.85M | 0.01% | 1482 |
|
|
2016
Q1 | $1.65M | Buy |
56,100
+52,800
| +1,600% | +$1.46M | ﹤0.01% | 2735 |
|
|
2015
Q4 | $87K | Buy |
3,300
+900
| +38% | +$23.4K | ﹤0.01% | 5484 |
|
|
2015
Q3 | $57K | Buy |
+2,400
| New | +$57.9K | ﹤0.01% | 5344 |
|
Other funds holding EW
VCM
VPM
Citigroup's EW Position: Q1 2026 in Review
Citigroup increased its Edwards Lifesciences (EW) stake by 27% in Q1 2026, buying an estimated $14M and bringing the position to 789,574 shares worth $63.2M. The position accounts for 0.03% of the portfolio, ranked #556.
Citigroup first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $108M in Q2 2025. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Citigroup held 789,574 shares of Edwards Lifesciences worth $63.2M as of Q1 2026.
- Citigroup bought 169,775 Edwards Lifesciences shares in Q1 2026, an estimated $14M.
- Edwards Lifesciences made up 0.03% of Citigroup's portfolio in Q1 2026, its #556 holding.
- Citigroup first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Edwards Lifesciences position peaked at $108M in Q2 2025.
- 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.